Skip to main content

Table 5 Rates of adverse events during treatment

From: Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study

Adverse effects Patients with advanced fibrosis (n) (%) (N =42) Patients without advanced fibrosis (n) (%) (N =126)
Dose modification 14 (33)* 19 (15)*
PegIFN 2 (5) 2 (2)
RBV 12 (29) 19 (15)
General disorder   
Fatigue 15 (36) 47 (37)
Fever 9 (21) 31 (25)
Rigor 7 (17) 15 (12)
Headache 4 (10) 15 (12)
Asthenia 4 (10) 10 (8)
Dizziness 11 (26) 34 (27)
Weight loss 0 (0) 5 (4)
Gastrointestinal effects   
Abdominal pain 9 (21) 25 (20)
Anorexia 15 (36) 32 (26)
Nausea 3 (7) 10 (8)
Vomiting 0 (0) 5 (4)
Diarrhea 3 (7) 6 (5)
Constipation 1 (2) 3 (2)
Psychiatric effects   
Depression 2 (5) 15 (12)
Insomnia 15 (36) 35 (28)
Anxiety 2 (5) 3 (2)
Respiratory effects   
Cough 8 (19) 26 (21)
Dyspnea 13 (31) 25 (20)
Rhinorrhea 0 (0) 7 (6)
Sore throat 2 (5) 6 (5)
Epistaxis 0 (0) 3 (2)
Neuromuscular effects   
Myalgia 11 (26) 28 (22)
Arthralgia 2 (5) 6 (5)
Numbness 2 (5) 6 (5)
Dermatologic effects   
Pruritus 18 (43) 46 (37)
Alopecia 6 (14) 18 (14)
Rash 8 (21) 19 (15)
Dry skin 2 (5) 2 (2)
Injection site irritation 0 (0) 2 (2)
Hematologic effects   
Anemiaa 13 (31)** 20 (16)**
Leukopeniab 5 (12) 8 (6)
Thrombocytopeniac 11 (26)*** 7 (6)***
EPO 11 (26) 17 (14)
BT 3 (7) 5 (4)
  1. EPO, erythropoietin; BT, blood transfusion.
  2. *p = 0.01; **p < 0.05; ***P < 0.001.
  3. ahemoglobin level <8.5 g/dL.
  4. bwhite blood cell count <1500 cells/mm3.
  5. cplatelet count <50,000 cells/mm.